Published Date: 10 Mar 2023
United States: The US research team recommended using a different agent to enhance the Doppler profile for more accurate measurements.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma
2.
Combination therapy improves outcomes for advanced triple-negative breast cancer
3.
When performed by skilled surgeons, robotic surgery for pancreatic tumors is safe and feasible.
4.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
5.
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival
1.
The Algorithmic Oncologist: A Comparative Clinical Review of AI in Predictive Cancer Planning
2.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
3.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Fibroma: Understanding the Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation